cat no | io1003
ioGABAergic Neurons are human induced pluripotent stem cell (iPSC)-derived GABAergic neurons, deterministically programmed using opti-ox technology. Within 4 days post-revival, ioGABAergic Neurons form a highly pure (>99%), defined population that is ready for experimentation, expressing classical marker genes including GAD1, GAD2, VGAT, DLX1 and DLX2. These inhibitory neurons display spontaneous activity as demonstrated by calcium imaging. ioGABAergic Neurons are also suitable for co-culture and tri-culture studies with ioGlutamatergic Neurons and Astrocytes to gain insights into complex intercellular interactions.
ioGABAergic Neurons provide a highly pure, consistent, functional and easy to use human iPSC-based model for the study of neural circuits, and for neurological disease research and drug development.
Confidently investigate your phenotype of interest across multiple clones with our disease model clone panel. Detailed characterisation data (below) and bulk RNA sequencing data (upon request) help you select specific clones if required.
per vial
A maximum number of 20 vials applies. If you would like to order more than 20 vials, please contact us at orders@bit.bio.
Highly Pure
>99% of cells express key GABAergic markers within 4 days post-thaw, confirmed by single cell RNA sequencing.
Consistent
Get reproducible results from every vial with high lot-to-lot consistency, with less than 1% differentially expressed genes between lots, confirmed by bulk-RNA sequencing.
Co-culture compatible
Forms functional neuronal networks within co-cultures with ioGlutamatergic Neurons and astrocytes as shown by microelectrode array (MEA) analysis.
opti-ox precision deterministically programmed ioGABAergic Neurons rapidly form a homogenous neuronal population
ioGABAergic Neurons express key GABAergic neuron-specific markers
ioGABAergic Neurons show visible neuronal networks by day 10
Single cell RNA-sequencing shows ioGABAergic Neurons form a pure population (>99%) of GABAergic neurons
Single cell RNA-sequencing shows ioGABAergic Neurons express key GABAergic markers
Single cell RNA-sequencing shows ioGABAergic Neurons display minimal expression of markers indicative of other neuronal lineages
Single cell RNA-sequencing indicates that ioGABAergic Neurons are of the SST sub-type
Whole transcriptome analysis demonstrates high lot-to-lot consistency of ioGABAergic Neurons
Calcium imaging of ioGABAergic Neurons demonstrates spontaneous activity
ioGABAergic Neurons form functional neuronal networks and modulate network activity in tri-cultures with ioGlutamatergic Neurons and astrocytes
ioGABAergic Neurons exert an inhibitory effect on the excitatory ioGlutamatergic Neurons within the tri-cultures leading to a higher network burst rate
Addition of bicuculline, a competitive antagonist of GABAA receptors, to the tri-cultures releases the inhibitory effect of the ioGABAergic Neurons
Addition of diazepam, a positive allosteric modulator of GABAA receptors, to the tri-cultures increases the inhibitory effect of the ioGABAergic Neurons
Dr Brian Gill, MD | Assistant Professor of Neurological Surgery| Columbia University Irving Medical Center
Dr Tony Oosterveen | Principal Scientist and CNS Lead, Neurobiology | bit.bio
Whitehouse, et al
JoVE Journal of Visualized Experiments
2023
Using ioGlutamatergic Neurons
Dr Ania Wilczynska | Head of Computational Genomics | Non-Clinical | bit.bio
V6
bit.bio
2023
Innovation showcase talk at ISSCR
Marius Wernig MD, PhD | Stanford
Mark Kotter, MD, PhD | bit.bio
Prof Roger Pedersen | Adjunct Professor and Senior Research Scientist at Stanford University
Dr Thomas Moreau | Director of Cell Biology Research | bit.bio
Mark Kotter | CEO and founder | bit.bio
Marius Wernig | Professor Departments of Pathology and Chemical and Systems Biology | Stanford University
In this webinar, Dr Rodney Bowling, CSO of Everlum Bio, offers an expert discussion on their use of ioGABAergic neurons for the screening of antisense oligonucleotide (ASO) based RNA therapeutics to accelerate the discovery of novel personalised therapies for rare autism spectrum disorders (ASD).
Rodney A. Bowling Jr., Ph.D.
Co-Founder & Chief Scientific Officer | Everlum Bio